Lv1
42 积分 2024-07-09 加入
B7-H4 in cancer immune evasion and immunotherapy
20天前
已完结
Incidence and clinical features of cataracts: an under-recognized adverse event with mirvetuximab soravtansine-gynx in ovarian cancer
20天前
已关闭
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
1个月前
已完结
HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications
1个月前
已关闭
Endometriosis and ovarian cancer: epidemiological evidence, molecular insights, and clinical decision-making
1个月前
已关闭
ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancer
2个月前
已完结
Guideline for the management pathway and quality control of ovarian cancer diagnosis and treatment in county-level regions of China (2025 Edition)
3个月前
已关闭
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
3个月前
已完结
The first Chinese National Union of Real-world Gynaecological Oncology Research and Patient Management Platform: A retrospective study
5个月前
已完结
Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR -Mutant Lung Adenocarcinomas
7个月前
已完结
皖公网安备34019202002308
